PARIS--(BUSINESS WIRE)--Regulatory News:
OSE Pharma SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE), an immuno-oncology company developing a T-specific immunotherapy, currently in a registration Phase 3 study, today announces financial annual results for 2015 as well as key achievements and the company’s outlook for 2016.
“2015 was a transformational year for OSE Pharma, beginning with a successful IPO supported by our shareholders and investors which funded the Phase 3 clinical trial of Tedopi® in lung cancer. Through the year we completed, on schedule, all of the preparatory steps for the study, which, today, is open in Europe and in the USA, with first patients having been recruited and treated,” commented Dominique Costantini, Chief Executive Officer of OSE Pharma. “Looking ahead, we are confident that in the coming year we will continue to deliver transformative steps and open additional growth prospects, in particular as a result of our merger project with Effimune which was announced at the end of February 2016. The combination of the two companies will create a reference group in activation and regulation immunotherapies, with a deeper clinical pipeline, teams with a strong common ambition, and technologies which act on the immune system to offer more efficient treatments to patients with severe pathologies.”
